SKSusanna Klevebro

Susanna Klevebro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susanna Klevebro has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Inger Kull

    Department of Clinical Science and education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden

    6 shared publications
  • Erik Melén

    Department of Clinical Science and education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden

    5 shared publications
  • Sophia Björkander

    Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

    5 shared publications
  • Anna Bergström

    Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden

    4 shared publications
  • Boubou Hallberg

    Department of Neonatology, Karolinska Institutet and University Hospital, Stockholm, Sweden

    4 shared publications
  • Simon Kebede Merid

    Department of Clinical Science and education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden

    4 shared publications

Latest Publications

  • Open Access

    Early-life serum protein profiles associated with bronchopulmonary dysplasia in extremely preterm infants

    by Susanna Klevebro, Mohit B. Panwar, Dirk Wackernagel, Ingrid Hansen Pupp, Sophia Björkander, Hanna Danielsson, Mathias Uhlén, Liv Vallin, Karin Sävman, Aldina Pivodic, et al.

    Background: Bronchopulmonary dysplasia (BPD) affects the most immature preterm infants and can result in long term pulmonary morbidity. Yet, how prenatal and neonatal exposures perturb early proteome maturation and contribute to BPD pathogenesis remains unclear. Methods: In a cohort of 176 extremely preterm infants (born < 28 weeks gestational age) previously enrolled in a multicenter randomized trial, 825 longitudinal serum samples were collected the first five postnatal weeks. 98 of 176 infants were defined as having BPD based on need for any respiratory support at 36 weeks postnatal age. Proteomic analysis was conducted using proximity extension assay from Olink. Mixed models, adjusted for gestational age, study center, and randomization group, also including an interaction term between BPD and time, were used to analyse differences in longitudinal protein trajectories by BPD status. False discovery rate correction was applied. Results: Out of 538 analysed proteins, 108 exhibited distinct longitudinal trajectories in infants with BPD. Among the top significant proteins, several have previously been associated with BPD (e.g. lower Secretoglobin family 3A member 1 [SCGB3A1] and higher intercellular adhesion molecule 1 [ICAM-1]), while others represent novel findings (e.g. lower Leukocyte differentiation antigen CD84). Network and functional enrichment analysis revealed involvement in multiple biological processes, with many of the top significant proteins related to immune function. Some proteins showed associations specific to more mature infants (e.g. Stem cell factor). Conclusion: Differences in early serum protein trajectories are evident in infants who develop BPD. Our findings suggest associations consistent with proposed pathophysiological mechanisms. Clinical factors likely interact with immune-related proteins in the development of BPD. Mitigating inflammation by stabilising potential protective factors could be important for BPD prevention. Trial registration: ClinicalTrial.gov identifier NCT03201588.

  • Open Access

    Long-term exposure to air pollution and metabolites in children and young adults in a Swedish birth cohort

    by Shizhen He, Baninia Habchi, Romanas Chaleckis, Natalia Hernandez-Pacheco, Anna Bergström, Anne-Sophie Merritt, Inger Kull, Kristina Eneroth, Matteo Bottai, Göran Pershagen, et al.

    Background: The biochemical dysregulation underlying the adverse health effects of exposure to air pollution (AP) remains unclear. Objective: The objective of this study was to explore associations between long-term exposure to AP and the urinary metabolome. Methods: In the Swedish birth cohort BAMSE ( n = 4089), urine samples were collected from a subset of participants attending clinical examination at the 4-year follow-up and from all participants attending clinical examination at the 24-year follow-up. Among paired samples and children with diagnosis of asthma and/or low lung function, non-targeted screening using liquid chromatography high-resolution mass spectrometry was applied to 4-year samples ( n = 612) and 24-year samples ( n = 846) and metabolites were annotated based on standard matching to in-house compound libraries ( n = 260 metabolites). Time-weighted average exposure to air pollutants ( i.e ., particulate matter with diameter ≤10μm (PM 10 ), ≤2.5 μm (PM 2.5 ), and nitrogen oxides (NO x )) during the first year of life and the year prior to urine collection was estimated using validated dispersion models. The association between AP exposure and urine metabolites was estimated cross-sectionally using exponential regression. Results: AP exposure was overall positively associated with metabolite abundance ( p < 0.002). However, metabolite-specific associations exhibited variability. At the 4-year follow-up, the first-year-of-life and prior-year AP exposures were positively associated with 8 purine/pyrimidine derivative metabolites ( e.g ., an increase of 2.8 μg/m 3 (interquartile range) in PM 10 during the first year of life was associated with a 1.21-fold increase in 1,7-dimethylxanthine, p = 3.87E−05). We also observed interactions between AP exposures and metabolism-related genetic variants on metabolite levels. At the 24-year follow-up, prior year AP was negatively associated with levels of six long-chain fatty acids. Impact: Long-term exposure to air pollution alters urinary metabolites in children and young adults, revealing environmental impacts on systemic metabolism even at low levels of air pollution.


  • Open Access

    Genetically Determined Inflammation‐Related Proteins in Asthma and Type‐2 Signatures

    by Natalia Hernandez‐Pacheco, Sophia Björkander, Simon Kebede Merid, Maura Kere, Ashish Kumar, Susanna Klevebro, Ida Mogensen, Sandra Ekström, Christer Janson, Lena Palmberg, et al.

    Background: Protein quantitative trait loci (pQTLs) remain underexplored in asthma but might provide valuable insights into the underlying molecular mechanisms. This study aimed to investigate associations between genetic variation and inflammation‐related plasma proteins and to assess differences in the levels of genetically determined proteins in subjects with signatures of type‐2 inflammation and/or asthma.Methods: A pQTL mapping of 92 inflammation‐related plasma proteins was conducted in young adults from the Swedish BAMSE cohort (n = 1538). Replication of sentinel pQTLs was attempted, and the overlap and colocalization of pQTLs with expression quantitative trait loci (eQTLs) were investigated using publicly available data. Proteins with significant pQTLs were tested for association with type‐2 signatures defined as high levels of fractional exhaled nitric oxide, blood eosinophils, and/or sensitization to airborne allergens in subjects with or without asthma in BAMSE.Results: Forty‐five sentinel pQTLs (33 cis, 12 trans) for 39 inflammation‐related proteins were identified (p ≤ 7.14 × 10−11), and a high proportion of these were validated in independent populations. A high likelihood for colocalization of cis‐pQTLs and cis‐eQTLs was observed for 19 proteins in different tissues. Six of the 39 circulating proteins with significant pQTLs were associated with type‐2 signatures and/or asthma, and matrix metalloproteinase‐10 (MMP‐10) showed the most significant associations.Conclusions: These findings underscore the existence of a genetic component influencing the plasma levels of proteins involved in inflammatory processes, including MMP‐10, which is suggested to have a role in high type‐2 inflammation in asthma subjects.


  • Urine metabolomics and asthma in children and young adults.

    by Susanna Klevebro, Beninia Habchi, Shizhen He, Sophia Björkander, Sandra Ekström, Zhebin Yu, Inger Kull, Anna Bergström, Romanas Chaleckis, Craig Wheelock, et al.

    Aim: The objective of this study was to evaluate potential biomarkers linked to asthma and its phenotypes in children and young adults. Methods: Non-targeted screening (NTS) using high-resolution mass spectrometry was performed on 608 urine samples from 4-year-olds and 845 samples from 24-year-olds collected in the Swedish birth cohort BAMSE. From the measured features, 260 metabolites were annotated using in-house compound libraries. Asthma was divided into allergic and non-allergic asthma based on presence of IgE to common allergens. Metabolites exhibiting significant variations (>1.5 or <0.67 in median peak area) and nominal p-value <0.05 in non-parametric tests were further analyzed. Results: Overall, no metabolites were associated with significant differences between participants with or without asthma at 4 or 24 years. However, 16 metabolites at 4 years and 23 metabolites at 24 years were associated with allergic- or non-allergic asthma phenotypes, whereof five metabolites were identical in both age groups. At 24 years of age, the subjects with non-allergic asthma (n=66) had higher abundance of 21 metabolites compared to both the group with allergic asthma (n=196) and the groups without asthma (n=570). Only one metabolite had differing abundance in subjects with allergic asthma. Conclusion: NTS using high-resolution mass spectrometry enabled identification of urine metabolites associated with in particular non-allergic asthma. erj;64/suppl_68/PA4050/F1 F1 F1

  • Open Access

    Arachidonic acid and docosahexaenoic acid levels correlate with the inflammation proteome in extremely preterm infants

    by Susanna Klevebro, Simon Kebede Merid, Ulrika Sjöbom, Wen Zhong, Hanna Danielsson, Dirk Wackernagel, Ingrid Hansen-Pupp, David Ley, Karin Sävman, Mathias Uhlén, et al.


  • Open Access

    High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small Children Oral Immunotherapy (SmaChO) Randomized Controlled Trial

    by Carina Uhl, Susanna Klevebro, Eva Sverremark-Ekström, Sandra G. Tedner, Josef Brandström, Chrystalleni Papageorgiou, Erik Melén, Jon R. Konradsen, Caroline Nilsson, Anna Asarnoj


  • Open Access

    Obese asthma phenotypes display distinct plasma biomarker profiles

    by Sophia Björkander, Susanna Klevebro, Natalia Hernandez‐Pacheco, Maura Kere, Sandra Ekström, Maria Sparreman Mikus, Marianne van Hage, Anna James, Inger Kull, Anna Bergström, et al.

    Background: Obese asthma is a complex phenotype and further characterization of the pathophysiology is needed. This study aimed to explore inflammation‐related plasma biomarkers in lean and overweight/obese asthmatics.Methods: We elucidated levels of inflammation‐related plasma proteins in obese asthma phenotypes in the population‐based cohort BAMSE (Swedish: Children, Allergy, Milieu, Stockholm, Epidemiology) using data from 2069 24‐26‐year‐olds. Subjects were divided into lean asthma (n = 166), lean controls (n = 1440), overweight/obese asthma (n = 73) and overweight/obese controls (n = 390). Protein levels (n = 92) were analysed using the Olink Proseek Multiplex Inflammation panel.Results: Of the 92 included proteins, 41 were associated with lean and/or overweight/obese asthma. The majority of proteins associated with overweight/obese asthma also associated with overweight/obesity among non‐asthmatics. Beta‐nerve growth factor (BetaNGF), interleukin 10 (IL‐10), and matrix metalloproteinase 10 (MMP10) were associated only with lean asthma while C‐C motif chemokine 20 (CCL20), fibroblast growth factor 19 (FGF19), interleukin 5 (IL‐5), leukemia inhibitory factor (LIF), tumor necrosis factor ligand superfamily member 9 (TNFRSF9), and urokinase‐type plasminogen activator (uPA) were associated only with overweight/obese asthma. Overweight/obesity modified the association between asthma and 3 of the proteins: fibroblast growth factor 21 (FGF21), interleukin 4 (IL‐4), and urokinase‐type plasminogen activator (uPA). In the overweight/obese group, interleukin‐6 (IL‐6) was associated with non‐allergic asthma but not allergic asthma.Conclusion: These data indicate distinct plasma protein phenotypes in lean and overweight/obese asthmatics which, in turn, can impact upon therapeutic approaches.


  • Open Access

    Maternal and Neonatal Polyunsaturated Fatty Acid Intake and Risk of Neurodevelopmental Impairment in Premature Infants

    by Rory J. Heath, Susanna Klevebro, Thomas R. Wood

    The N3 and N6 long chain polyunsaturated fatty acids (LCPUFA) docosahexaenoic acid (DHA) and arachidonic acid (AA) are essential for proper neurodevelopment in early life. These fatty acids are passed from mother to infant via the placenta, accreting into fetal tissues such as brain and adipose tissue. Placental transfer of LCPUFA is highest in the final trimester, but this transfer is abruptly severed with premature birth. As such, efforts have been made to supplement the post-natal feed of premature infants with LCPUFA to improve neurodevelopmental outcomes. This narrative review analyzes the current body of evidence pertinent to neurodevelopmental outcomes after LCPUFA supplementation in prematurely born infants, which was identified via the reference lists of systematic and narrative reviews and PubMed search engine results. This review finds that, while the evidence is weakened by heterogeneity, it may be seen that feed comprising 0.3% DHA and 0.6% AA is associated with more positive neurodevelopmental outcomes than LCPUFA-deplete feed. While no new RCTs have been performed since the most recent Cochrane meta-analysis in 2016, this narrative review provides a wider commentary; the wider effects of LCPUFA supplementation in prematurely born infants, the physiology of LCPUFA accretion into preterm tissues, and the physiological effects of LCPUFA that affect neurodevelopment. We also discuss the roles of maternal LCPUFA status as a modifiable factor affecting the risk of preterm birth and infant neurodevelopmental outcomes. To better understand the role of LCPUFAs in infant neurodevelopment, future study designs must consider absolute and relative availabilities of all LCPUFA species and incorporate the LCPUFA status of both mother and infant in pre- and postnatal periods.


  • Open Access

    Potential SARS-CoV-2 infectiousness among asymptomatic healthcare workers

    by Ville N. Pimenoff, Miriam Elfström, Kalle Conneryd Lundgren, Susanna Klevebro, Erik Melen, Joakim Dillner

    A majority of SARS-CoV-2 infections are transmitted from a minority of infected subjects, some of which may be symptomatic or pre-symptomatic. We aimed to quantify potential infectiousness among asymptomatic healthcare workers (HCWs) in relation to prior or later symptomatic disease. We previously (at the onset of the SARS-CoV-2 epidemic) performed a cohort study of SARS-CoV-2 infections among 27,000 healthcare workers (HCWs) at work in the capital region of Sweden. We performed both SARS-CoV-2 RT-PCR and serology. Furthermore, the cohort was comprehensively followed for sick leave, both before and after sampling. In the present report, we used the cohort database to quantify potential infectiousness among HCWs at work. Those who had sick leave either before or after sampling were classified as post-symptomatic or pre-symptomatic, whereas the virus-positive subjects with no sick leave were considered asymptomatic. About 0.2% (19/9449) of HCW at work were potentially infectious and pre-symptomatic (later had disease) and 0.17% (16/9449) were potentially infectious and asymptomatic (never had sick leave either before nor after sampling). Thus, 33% and 28% of all the 57 potentially infectious subjects were pre-symptomatic or asymptomatic, respectively. When a questionnaire was administered to HCWs with past infection, only 10,5% of HCWs had had no indication at all of having had SARS-CoV-2 infection (“truly asymptomatic”). Our findings provide a unique quantification of the different groups of asymptomatic, potentially infectious HCWs.


  • Open Access

    Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care

    by Susanna Klevebro, Fuad Bahram, K. Miriam Elfström, Ulrika Hellberg, Sophia Hober, Simon Kebede Merid, Inger Kull, Peter Nilsson, Per Tornvall, Gang Wang, et al.

    Aim: We aimed to assess prevalence of IgG antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and factors associated with seropositivity in a large cohort of healthcare workers (HCWs). Methods: From 11 May until 11 June 2020, 3981 HCWs at a large Swedish emergency care hospital provided serum samples and questionnaire data. Presence of IgG antibodies to SARS-CoV-2 was measured as an indicator of SARS-CoV-2 exposure. Results: The total seroprevalence was 18% and increased during the study period. Among the seropositive HCWs, 11% had been entirely asymptomatic. Participants who worked with COVID-19 patients had higher odds for seropositivity: adjusted odds ratio 1.96 (95% confidence intervals 1.59–2.42). HCWs from three of the departments managing COVID-19 patients had significantly higher seroprevalences, whereas the prevalence among HCWs from the intensive care unit (also managing COVID-19 patients) was significantly lower. Conclusions: HCWs in contact with SARS-CoV-2 infected patients had a variable, but on average higher, likelihood for SARS-CoV-2 infections.